Cardiac perfusion changes in patients treated for breast cancer with radiation therapy and doxorubicin: preliminary results

Int J Radiat Oncol Biol Phys. 2001 Mar 15;49(4):1023-8. doi: 10.1016/s0360-3016(00)01531-5.

Abstract

Purpose: To determine the incidence and dose dependence of regional cardiac perfusion abnormalities in patients with left-sided breast cancer treated with radiation therapy (RT) with and without doxorubicin (Dox).

Methods: Twenty patients with left-sided breast cancer underwent cardiac perfusion imaging using single photon emission computed tomography (SPECT) prechemotherapy, pre-RT, and 6 months post-RT. SPECT perfusion images were registered onto 3-dimensional (3D) RT dose distributions. The volume of heart in the RT field was quantified, and the regional RT dose was calculated. A decrease in regional cardiac perfusion was assessed subjectively by visual inspection and objectively using image fusion software. Ten patients received Dox-based chemotherapy (total dose 120-300 mg/m(2)), and 10 patients had no chemotherapy. RT was delivered by tangent beams in all patients to a total dose of 46-50 Gy.

Results: Overall, 60% of the patients had new visible perfusion defects 6 months post-RT. A dose-dependent perfusion defect was seen at 6 months with minimal defect appreciated at 0-10 Gy, and a 20% decrease in regional perfusion at 41-50 Gy. One of 20 patients had a decrease in left ventricle ejection fraction (LVEF) of greater than 10% at 6 months; 2/20 patients had developed transient pericarditis. No instances of myocardial infarction or congestive heart failure (CHF) have occurred.

Conclusions: RT causes cardiac perfusion defects 6 months post-RT in most patients. Long-term follow-up is needed to assess whether these perfusion changes are transient or permanent and to determine if these findings are associated with changes in overall cardiac function and clinical outcome.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / therapeutic use
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / physiopathology
  • Breast Neoplasms / radiotherapy*
  • Combined Modality Therapy
  • Coronary Circulation / drug effects*
  • Coronary Circulation / radiation effects*
  • Dose-Response Relationship, Radiation
  • Doxorubicin / adverse effects*
  • Doxorubicin / therapeutic use
  • Female
  • Gated Blood-Pool Imaging / methods
  • Heart / diagnostic imaging
  • Heart / drug effects*
  • Heart / radiation effects*
  • Humans
  • Middle Aged
  • Prospective Studies
  • Radiotherapy Dosage
  • Tomography, Emission-Computed, Single-Photon / methods
  • Ventricular Function, Left / drug effects
  • Ventricular Function, Left / radiation effects

Substances

  • Antineoplastic Agents
  • Doxorubicin